nodes	percent_of_prediction	percent_of_DWPC	metapath
Sirolimus—FKBP1A—Cyclosporine—focal segmental glomerulosclerosis	0.484	0.663	CbGbCtD
Sirolimus—SLCO1B1—Cyclosporine—focal segmental glomerulosclerosis	0.08	0.11	CbGbCtD
Sirolimus—CYP3A7-CYP3A51P—Cyclosporine—focal segmental glomerulosclerosis	0.0469	0.0643	CbGbCtD
Sirolimus—CYP3A7—Cyclosporine—focal segmental glomerulosclerosis	0.0469	0.0643	CbGbCtD
Sirolimus—CYP3A5—Cyclosporine—focal segmental glomerulosclerosis	0.0352	0.0482	CbGbCtD
Sirolimus—ABCB1—Cyclosporine—focal segmental glomerulosclerosis	0.0229	0.0314	CbGbCtD
Sirolimus—Cyclosporine toxicity—Cyclosporine—focal segmental glomerulosclerosis	0.0214	0.108	CcSEcCtD
Sirolimus—CYP3A4—Cyclosporine—focal segmental glomerulosclerosis	0.0137	0.0188	CbGbCtD
Sirolimus—Infection susceptibility increased—Cyclosporine—focal segmental glomerulosclerosis	0.0123	0.0619	CcSEcCtD
Sirolimus—Renal graft loss—Cyclosporine—focal segmental glomerulosclerosis	0.0123	0.0619	CcSEcCtD
Sirolimus—Serum triglycerides increased—Cyclosporine—focal segmental glomerulosclerosis	0.0103	0.0518	CcSEcCtD
Sirolimus—Graft loss—Cyclosporine—focal segmental glomerulosclerosis	0.0103	0.0518	CcSEcCtD
Sirolimus—Lymphoproliferative disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00547	0.0275	CcSEcCtD
Sirolimus—X-linked lymphoproliferative syndrome—Cyclosporine—focal segmental glomerulosclerosis	0.00547	0.0275	CcSEcCtD
Sirolimus—Progressive multifocal leukoencephalopathy—Cyclosporine—focal segmental glomerulosclerosis	0.00547	0.0275	CcSEcCtD
Sirolimus—Wound—Cyclosporine—focal segmental glomerulosclerosis	0.0051	0.0257	CcSEcCtD
Sirolimus—EIF4E—kidney—focal segmental glomerulosclerosis	0.00447	0.204	CbGeAlD
Sirolimus—Haemolytic uraemic syndrome—Cyclosporine—focal segmental glomerulosclerosis	0.00339	0.0171	CcSEcCtD
Sirolimus—Gingival hyperplasia—Cyclosporine—focal segmental glomerulosclerosis	0.00275	0.0138	CcSEcCtD
Sirolimus—Toxicity to various agents—Cyclosporine—focal segmental glomerulosclerosis	0.00259	0.013	CcSEcCtD
Sirolimus—Thrombotic thrombocytopenic purpura—Cyclosporine—focal segmental glomerulosclerosis	0.00259	0.013	CcSEcCtD
Sirolimus—Carcinoma—Cyclosporine—focal segmental glomerulosclerosis	0.00245	0.0123	CcSEcCtD
Sirolimus—Skin cancer—Cyclosporine—focal segmental glomerulosclerosis	0.00239	0.012	CcSEcCtD
Sirolimus—Lymphoma—Cyclosporine—focal segmental glomerulosclerosis	0.00212	0.0107	CcSEcCtD
Sirolimus—Non-Hodgkin's lymphoma—Cyclosporine—focal segmental glomerulosclerosis	0.00212	0.0107	CcSEcCtD
Sirolimus—Renal tubular necrosis—Cyclosporine—focal segmental glomerulosclerosis	0.00207	0.0104	CcSEcCtD
Sirolimus—Pyelonephritis—Cyclosporine—focal segmental glomerulosclerosis	0.00195	0.00981	CcSEcCtD
Sirolimus—CYP3A7-CYP3A51P—nephron tubule—focal segmental glomerulosclerosis	0.00186	0.0849	CbGeAlD
Sirolimus—MTOR—kidney—focal segmental glomerulosclerosis	0.00173	0.0788	CbGeAlD
Sirolimus—Bacterial infection—Cyclosporine—focal segmental glomerulosclerosis	0.0016	0.00808	CcSEcCtD
Sirolimus—CYP3A7-CYP3A51P—cortex of kidney—focal segmental glomerulosclerosis	0.00159	0.0726	CbGeAlD
Sirolimus—Thrombocytopenic purpura—Cyclosporine—focal segmental glomerulosclerosis	0.00158	0.00795	CcSEcCtD
Sirolimus—FKBP1A—kidney—focal segmental glomerulosclerosis	0.00156	0.0709	CbGeAlD
Sirolimus—Nephropathy—Cyclosporine—focal segmental glomerulosclerosis	0.00155	0.00783	CcSEcCtD
Sirolimus—SLC47A1—nephron tubule—focal segmental glomerulosclerosis	0.00152	0.0693	CbGeAlD
Sirolimus—FKBP1A—cortex of kidney—focal segmental glomerulosclerosis	0.00152	0.0691	CbGeAlD
Sirolimus—Azotaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00139	0.007	CcSEcCtD
Sirolimus—SLC47A1—kidney—focal segmental glomerulosclerosis	0.00134	0.0609	CbGeAlD
Sirolimus—Urine abnormality—Cyclosporine—focal segmental glomerulosclerosis	0.00134	0.00673	CcSEcCtD
Sirolimus—SLCO1B1—kidney—focal segmental glomerulosclerosis	0.00132	0.0602	CbGeAlD
Sirolimus—SLC47A1—cortex of kidney—focal segmental glomerulosclerosis	0.0013	0.0593	CbGeAlD
Sirolimus—Nephropathy toxic—Cyclosporine—focal segmental glomerulosclerosis	0.00129	0.00649	CcSEcCtD
Sirolimus—Hypertriglyceridaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00129	0.00649	CcSEcCtD
Sirolimus—Hirsutism—Cyclosporine—focal segmental glomerulosclerosis	0.00127	0.00641	CcSEcCtD
Sirolimus—Urine analysis abnormal—Cyclosporine—focal segmental glomerulosclerosis	0.00126	0.00634	CcSEcCtD
Sirolimus—Polyp—Cyclosporine—focal segmental glomerulosclerosis	0.00122	0.00613	CcSEcCtD
Sirolimus—Hypomagnesaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00116	0.00587	CcSEcCtD
Sirolimus—Nail disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00114	0.00575	CcSEcCtD
Sirolimus—Blood triglycerides increased—Cyclosporine—focal segmental glomerulosclerosis	0.00113	0.00569	CcSEcCtD
Sirolimus—Cyst—Cyclosporine—focal segmental glomerulosclerosis	0.00111	0.00558	CcSEcCtD
Sirolimus—Menstrual disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00109	0.00547	CcSEcCtD
Sirolimus—Interstitial lung disease—Cyclosporine—focal segmental glomerulosclerosis	0.00105	0.00527	CcSEcCtD
Sirolimus—Thrombosis—Cyclosporine—focal segmental glomerulosclerosis	0.00105	0.00527	CcSEcCtD
Sirolimus—Hyperlipidaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00103	0.00517	CcSEcCtD
Sirolimus—Herpes zoster—Cyclosporine—focal segmental glomerulosclerosis	0.000983	0.00495	CcSEcCtD
Sirolimus—Hepatotoxicity—Cyclosporine—focal segmental glomerulosclerosis	0.000958	0.00483	CcSEcCtD
Sirolimus—Skin ulcer—Cyclosporine—focal segmental glomerulosclerosis	0.000951	0.00479	CcSEcCtD
Sirolimus—Gingivitis—Cyclosporine—focal segmental glomerulosclerosis	0.000943	0.00475	CcSEcCtD
Sirolimus—Abscess—Cyclosporine—focal segmental glomerulosclerosis	0.000935	0.00471	CcSEcCtD
Sirolimus—Acne—Cyclosporine—focal segmental glomerulosclerosis	0.000879	0.00443	CcSEcCtD
Sirolimus—Liver injury—Cyclosporine—focal segmental glomerulosclerosis	0.000879	0.00443	CcSEcCtD
Sirolimus—Neoplasm malignant—Cyclosporine—focal segmental glomerulosclerosis	0.000867	0.00437	CcSEcCtD
Sirolimus—Amenorrhoea—Cyclosporine—focal segmental glomerulosclerosis	0.000842	0.00424	CcSEcCtD
Sirolimus—FKBP1A—Spinal Cord Injury—COL4A1—focal segmental glomerulosclerosis	0.000831	0.0169	CbGpPWpGaD
Sirolimus—Viral infection—Cyclosporine—focal segmental glomerulosclerosis	0.000819	0.00413	CcSEcCtD
Sirolimus—Cellulitis—Cyclosporine—focal segmental glomerulosclerosis	0.000814	0.0041	CcSEcCtD
Sirolimus—Arthropathy—Cyclosporine—focal segmental glomerulosclerosis	0.000814	0.0041	CcSEcCtD
Sirolimus—Hyperbilirubinaemia—Cyclosporine—focal segmental glomerulosclerosis	0.000814	0.0041	CcSEcCtD
Sirolimus—Herpes simplex—Cyclosporine—focal segmental glomerulosclerosis	0.000803	0.00405	CcSEcCtD
Sirolimus—Hyperuricaemia—Cyclosporine—focal segmental glomerulosclerosis	0.000798	0.00402	CcSEcCtD
Sirolimus—Nocturia—Cyclosporine—focal segmental glomerulosclerosis	0.000798	0.00402	CcSEcCtD
Sirolimus—Gout—Cyclosporine—focal segmental glomerulosclerosis	0.000793	0.00399	CcSEcCtD
Sirolimus—Creatinine increased—Cyclosporine—focal segmental glomerulosclerosis	0.000777	0.00392	CcSEcCtD
Sirolimus—Cataract—Cyclosporine—focal segmental glomerulosclerosis	0.000777	0.00392	CcSEcCtD
Sirolimus—CYP3A5—nephron tubule—focal segmental glomerulosclerosis	0.000771	0.0351	CbGeAlD
Sirolimus—FGF2—Regulation of Actin Cytoskeleton—MYH10—focal segmental glomerulosclerosis	0.000768	0.0157	CbGpPWpGaD
Sirolimus—Blood uric acid increased—Cyclosporine—focal segmental glomerulosclerosis	0.000754	0.0038	CcSEcCtD
Sirolimus—Hepatocellular injury—Cyclosporine—focal segmental glomerulosclerosis	0.00074	0.00373	CcSEcCtD
Sirolimus—Hiccups—Cyclosporine—focal segmental glomerulosclerosis	0.00074	0.00373	CcSEcCtD
Sirolimus—Hyperkalaemia—Cyclosporine—focal segmental glomerulosclerosis	0.000727	0.00366	CcSEcCtD
Sirolimus—Eructation—Cyclosporine—focal segmental glomerulosclerosis	0.000727	0.00366	CcSEcCtD
Sirolimus—Urinary incontinence—Cyclosporine—focal segmental glomerulosclerosis	0.000715	0.0036	CcSEcCtD
Sirolimus—Candida infection—Cyclosporine—focal segmental glomerulosclerosis	0.000707	0.00356	CcSEcCtD
Sirolimus—Fluid retention—Cyclosporine—focal segmental glomerulosclerosis	0.000703	0.00354	CcSEcCtD
Sirolimus—Blood urea increased—Cyclosporine—focal segmental glomerulosclerosis	0.000699	0.00352	CcSEcCtD
Sirolimus—Neuropathy—Cyclosporine—focal segmental glomerulosclerosis	0.000695	0.0035	CcSEcCtD
Sirolimus—SLCO1B1—Transport of organic anions—ALB—focal segmental glomerulosclerosis	0.000688	0.014	CbGpPWpGaD
Sirolimus—Cramps of lower extremities—Cyclosporine—focal segmental glomerulosclerosis	0.00068	0.00342	CcSEcCtD
Sirolimus—CYP3A5—kidney—focal segmental glomerulosclerosis	0.000678	0.0309	CbGeAlD
Sirolimus—Oesophagitis—Cyclosporine—focal segmental glomerulosclerosis	0.000676	0.00341	CcSEcCtD
Sirolimus—Urine output increased—Cyclosporine—focal segmental glomerulosclerosis	0.000669	0.00337	CcSEcCtD
Sirolimus—Neoplasm—Cyclosporine—focal segmental glomerulosclerosis	0.000669	0.00337	CcSEcCtD
Sirolimus—FKBP1A—TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)—TGFB1—focal segmental glomerulosclerosis	0.000667	0.0136	CbGpPWpGaD
Sirolimus—CYP3A5—cortex of kidney—focal segmental glomerulosclerosis	0.00066	0.0301	CbGeAlD
Sirolimus—Abnormal vision—Cyclosporine—focal segmental glomerulosclerosis	0.000645	0.00325	CcSEcCtD
Sirolimus—Sepsis—Cyclosporine—focal segmental glomerulosclerosis	0.000642	0.00324	CcSEcCtD
Sirolimus—Lymphadenopathy—Cyclosporine—focal segmental glomerulosclerosis	0.00063	0.00317	CcSEcCtD
Sirolimus—Diabetes mellitus—Cyclosporine—focal segmental glomerulosclerosis	0.000618	0.00311	CcSEcCtD
Sirolimus—EIF4E—Cytokine Signaling in Immune system—PIAS1—focal segmental glomerulosclerosis	0.000617	0.0126	CbGpPWpGaD
Sirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—PIAS1—focal segmental glomerulosclerosis	0.000615	0.0125	CbGpPWpGaD
Sirolimus—Polyuria—Cyclosporine—focal segmental glomerulosclerosis	0.000612	0.00308	CcSEcCtD
Sirolimus—Gastroenteritis—Cyclosporine—focal segmental glomerulosclerosis	0.000606	0.00305	CcSEcCtD
Sirolimus—Deafness—Cyclosporine—focal segmental glomerulosclerosis	0.000601	0.00303	CcSEcCtD
Sirolimus—Hepatic failure—Cyclosporine—focal segmental glomerulosclerosis	0.000598	0.00301	CcSEcCtD
Sirolimus—FGF2—Angiopoietin receptor Tie2-mediated signaling—AGTR1—focal segmental glomerulosclerosis	0.000594	0.0121	CbGpPWpGaD
Sirolimus—Injury—Cyclosporine—focal segmental glomerulosclerosis	0.000584	0.00294	CcSEcCtD
Sirolimus—FKBP1A—TGF-beta Receptor Signaling—SPP1—focal segmental glomerulosclerosis	0.000575	0.0117	CbGpPWpGaD
Sirolimus—Increased appetite—Cyclosporine—focal segmental glomerulosclerosis	0.000572	0.00288	CcSEcCtD
Sirolimus—Renal impairment—Cyclosporine—focal segmental glomerulosclerosis	0.000564	0.00284	CcSEcCtD
Sirolimus—Anaphylactoid reaction—Cyclosporine—focal segmental glomerulosclerosis	0.000555	0.0028	CcSEcCtD
Sirolimus—FGF2—Syndecan-4-mediated signaling events—FN1—focal segmental glomerulosclerosis	0.000552	0.0113	CbGpPWpGaD
Sirolimus—Hypoglycaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00055	0.00277	CcSEcCtD
Sirolimus—Osteoarthritis—Cyclosporine—focal segmental glomerulosclerosis	0.000537	0.00271	CcSEcCtD
Sirolimus—Affect lability—Cyclosporine—focal segmental glomerulosclerosis	0.000529	0.00266	CcSEcCtD
Sirolimus—MTOR—Regulation of Telomerase—WT1—focal segmental glomerulosclerosis	0.000522	0.0106	CbGpPWpGaD
Sirolimus—SLCO1B1—Recycling of bile acids and salts—ALB—focal segmental glomerulosclerosis	0.00051	0.0104	CbGpPWpGaD
Sirolimus—Mood swings—Cyclosporine—focal segmental glomerulosclerosis	0.000509	0.00256	CcSEcCtD
Sirolimus—CYP3A4—kidney—focal segmental glomerulosclerosis	0.000508	0.0232	CbGeAlD
Sirolimus—Blood creatinine increased—Cyclosporine—focal segmental glomerulosclerosis	0.000503	0.00254	CcSEcCtD
Sirolimus—Breast disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000485	0.00245	CcSEcCtD
Sirolimus—FGF2—Signaling by PDGF—COL4A4—focal segmental glomerulosclerosis	0.000484	0.00988	CbGpPWpGaD
Sirolimus—Gastritis—Cyclosporine—focal segmental glomerulosclerosis	0.000475	0.0024	CcSEcCtD
Sirolimus—Abdominal distension—Cyclosporine—focal segmental glomerulosclerosis	0.000467	0.00235	CcSEcCtD
Sirolimus—FGF2—Integrated Pancreatic Cancer Pathway—PIAS1—focal segmental glomerulosclerosis	0.000466	0.0095	CbGpPWpGaD
Sirolimus—Dysphagia—Cyclosporine—focal segmental glomerulosclerosis	0.000464	0.00234	CcSEcCtD
Sirolimus—Pancreatitis—Cyclosporine—focal segmental glomerulosclerosis	0.000455	0.00229	CcSEcCtD
Sirolimus—FKBP1A—ALK1 signaling events—TGFB1—focal segmental glomerulosclerosis	0.000452	0.00922	CbGpPWpGaD
Sirolimus—Bronchitis—Cyclosporine—focal segmental glomerulosclerosis	0.000447	0.00225	CcSEcCtD
Sirolimus—FGF2—Signaling by PDGF—COL4A1—focal segmental glomerulosclerosis	0.000445	0.00908	CbGpPWpGaD
Sirolimus—FGF2—Angiogenesis—MMP9—focal segmental glomerulosclerosis	0.000443	0.00904	CbGpPWpGaD
Sirolimus—Dysuria—Cyclosporine—focal segmental glomerulosclerosis	0.000434	0.00219	CcSEcCtD
Sirolimus—Upper respiratory tract infection—Cyclosporine—focal segmental glomerulosclerosis	0.000432	0.00217	CcSEcCtD
Sirolimus—Pollakiuria—Cyclosporine—focal segmental glomerulosclerosis	0.000429	0.00216	CcSEcCtD
Sirolimus—FGF2—Syndecan interactions—TGFB1—focal segmental glomerulosclerosis	0.000423	0.00862	CbGpPWpGaD
Sirolimus—Weight increased—Cyclosporine—focal segmental glomerulosclerosis	0.000423	0.00213	CcSEcCtD
Sirolimus—Weight decreased—Cyclosporine—focal segmental glomerulosclerosis	0.00042	0.00212	CcSEcCtD
Sirolimus—Hyperglycaemia—Cyclosporine—focal segmental glomerulosclerosis	0.000419	0.00211	CcSEcCtD
Sirolimus—MTOR—Integrated Breast Cancer Pathway—PIAS1—focal segmental glomerulosclerosis	0.000417	0.00851	CbGpPWpGaD
Sirolimus—Pneumonia—Cyclosporine—focal segmental glomerulosclerosis	0.000416	0.0021	CcSEcCtD
Sirolimus—Infestation—Cyclosporine—focal segmental glomerulosclerosis	0.000414	0.00209	CcSEcCtD
Sirolimus—Infestation NOS—Cyclosporine—focal segmental glomerulosclerosis	0.000414	0.00209	CcSEcCtD
Sirolimus—ABCB1—nephron tubule—focal segmental glomerulosclerosis	0.00041	0.0187	CbGeAlD
Sirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—WT1—focal segmental glomerulosclerosis	0.000406	0.00828	CbGpPWpGaD
Sirolimus—Neuropathy peripheral—Cyclosporine—focal segmental glomerulosclerosis	0.000406	0.00204	CcSEcCtD
Sirolimus—Stomatitis—Cyclosporine—focal segmental glomerulosclerosis	0.000404	0.00203	CcSEcCtD
Sirolimus—Conjunctivitis—Cyclosporine—focal segmental glomerulosclerosis	0.000402	0.00203	CcSEcCtD
Sirolimus—Urinary tract infection—Cyclosporine—focal segmental glomerulosclerosis	0.000402	0.00203	CcSEcCtD
Sirolimus—FKBP1A—TGF-beta Receptor Signaling—SERPINE1—focal segmental glomerulosclerosis	0.000399	0.00814	CbGpPWpGaD
Sirolimus—Haematuria—Cyclosporine—focal segmental glomerulosclerosis	0.000395	0.00199	CcSEcCtD
Sirolimus—Hepatobiliary disease—Cyclosporine—focal segmental glomerulosclerosis	0.000392	0.00197	CcSEcCtD
Sirolimus—Epistaxis—Cyclosporine—focal segmental glomerulosclerosis	0.00039	0.00197	CcSEcCtD
Sirolimus—Sinusitis—Cyclosporine—focal segmental glomerulosclerosis	0.000388	0.00196	CcSEcCtD
Sirolimus—FGF2—Angiopoietin receptor Tie2-mediated signaling—FN1—focal segmental glomerulosclerosis	0.000387	0.00788	CbGpPWpGaD
Sirolimus—MTOR—TSH signaling pathway—GNAQ—focal segmental glomerulosclerosis	0.000386	0.00788	CbGpPWpGaD
Sirolimus—FGF2—Integrins in angiogenesis—SPP1—focal segmental glomerulosclerosis	0.000385	0.00785	CbGpPWpGaD
Sirolimus—FKBP1A—TGF-beta receptor signaling activates SMADs—TGFB1—focal segmental glomerulosclerosis	0.000383	0.00781	CbGpPWpGaD
Sirolimus—FGF2—Endochondral Ossification—SPP1—focal segmental glomerulosclerosis	0.00038	0.00775	CbGpPWpGaD
Sirolimus—Tacrolimus—ALB—focal segmental glomerulosclerosis	0.000378	1	CrCbGaD
Sirolimus—FGF2—Signaling by PDGF—COL4A3—focal segmental glomerulosclerosis	0.000376	0.00767	CbGpPWpGaD
Sirolimus—Haemoglobin—Cyclosporine—focal segmental glomerulosclerosis	0.000374	0.00188	CcSEcCtD
Sirolimus—Rhinitis—Cyclosporine—focal segmental glomerulosclerosis	0.000373	0.00188	CcSEcCtD
Sirolimus—Haemorrhage—Cyclosporine—focal segmental glomerulosclerosis	0.000372	0.00187	CcSEcCtD
Sirolimus—Hypoaesthesia—Cyclosporine—focal segmental glomerulosclerosis	0.00037	0.00186	CcSEcCtD
Sirolimus—Pharyngitis—Cyclosporine—focal segmental glomerulosclerosis	0.000369	0.00186	CcSEcCtD
Sirolimus—Urinary tract disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000367	0.00185	CcSEcCtD
Sirolimus—Connective tissue disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000365	0.00184	CcSEcCtD
Sirolimus—Urethral disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000364	0.00184	CcSEcCtD
Sirolimus—ABCB1—kidney—focal segmental glomerulosclerosis	0.00036	0.0164	CbGeAlD
Sirolimus—FGF2—Extracellular matrix organization—COL4A4—focal segmental glomerulosclerosis	0.00036	0.00734	CbGpPWpGaD
Sirolimus—MTOR—Signaling by PDGF—COL4A4—focal segmental glomerulosclerosis	0.000359	0.00733	CbGpPWpGaD
Sirolimus—Visual impairment—Cyclosporine—focal segmental glomerulosclerosis	0.000358	0.0018	CcSEcCtD
Sirolimus—FKBP1A—Calcium Regulation in the Cardiac Cell—GNAQ—focal segmental glomerulosclerosis	0.000358	0.0073	CbGpPWpGaD
Sirolimus—EIF4E—BDNF signaling pathway—SPP1—focal segmental glomerulosclerosis	0.000357	0.00729	CbGpPWpGaD
Sirolimus—FGF2—Syndecan-4-mediated signaling events—MMP9—focal segmental glomerulosclerosis	0.000352	0.00718	CbGpPWpGaD
Sirolimus—ABCB1—cortex of kidney—focal segmental glomerulosclerosis	0.000351	0.016	CbGeAlD
Sirolimus—Tinnitus—Cyclosporine—focal segmental glomerulosclerosis	0.000346	0.00175	CcSEcCtD
Sirolimus—FGF2—Glypican 1 network—TGFB1—focal segmental glomerulosclerosis	0.000343	0.00699	CbGpPWpGaD
Sirolimus—Angiopathy—Cyclosporine—focal segmental glomerulosclerosis	0.000337	0.0017	CcSEcCtD
Sirolimus—Mediastinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000335	0.00169	CcSEcCtD
Sirolimus—Chills—Cyclosporine—focal segmental glomerulosclerosis	0.000333	0.00168	CcSEcCtD
Sirolimus—FGF2—MicroRNAs in cardiomyocyte hypertrophy—EDN1—focal segmental glomerulosclerosis	0.000333	0.00679	CbGpPWpGaD
Sirolimus—FGF2—Extracellular matrix organization—COL4A1—focal segmental glomerulosclerosis	0.000331	0.00674	CbGpPWpGaD
Sirolimus—MTOR—Signaling by PDGF—COL4A1—focal segmental glomerulosclerosis	0.00033	0.00674	CbGpPWpGaD
Sirolimus—FGF2—Angiopoietin receptor Tie2-mediated signaling—MMP2—focal segmental glomerulosclerosis	0.000328	0.00668	CbGpPWpGaD
Sirolimus—FKBP1A—Loss of Function of SMAD2/3 in Cancer—SERPINE1—focal segmental glomerulosclerosis	0.000324	0.00661	CbGpPWpGaD
Sirolimus—Malnutrition—Cyclosporine—focal segmental glomerulosclerosis	0.000324	0.00163	CcSEcCtD
Sirolimus—FGF2—Integrins in angiogenesis—FN1—focal segmental glomerulosclerosis	0.000321	0.00655	CbGpPWpGaD
Sirolimus—Flatulence—Cyclosporine—focal segmental glomerulosclerosis	0.000319	0.00161	CcSEcCtD
Sirolimus—Tension—Cyclosporine—focal segmental glomerulosclerosis	0.000317	0.0016	CcSEcCtD
Sirolimus—Nervousness—Cyclosporine—focal segmental glomerulosclerosis	0.000314	0.00158	CcSEcCtD
Sirolimus—MTOR—IL4-mediated signaling events—CD40LG—focal segmental glomerulosclerosis	0.000311	0.00635	CbGpPWpGaD
Sirolimus—Muscle spasms—Cyclosporine—focal segmental glomerulosclerosis	0.000311	0.00157	CcSEcCtD
Sirolimus—FGF2—Integrated Pancreatic Cancer Pathway—WT1—focal segmental glomerulosclerosis	0.000308	0.00627	CbGpPWpGaD
Sirolimus—EIF4E—Validated targets of C-MYC transcriptional activation—MMP9—focal segmental glomerulosclerosis	0.000307	0.00627	CbGpPWpGaD
Sirolimus—Tremor—Cyclosporine—focal segmental glomerulosclerosis	0.000303	0.00153	CcSEcCtD
Sirolimus—Ill-defined disorder—Cyclosporine—focal segmental glomerulosclerosis	0.0003	0.00151	CcSEcCtD
Sirolimus—Anaemia—Cyclosporine—focal segmental glomerulosclerosis	0.000299	0.00151	CcSEcCtD
Sirolimus—Agitation—Cyclosporine—focal segmental glomerulosclerosis	0.000297	0.0015	CcSEcCtD
Sirolimus—Angioedema—Cyclosporine—focal segmental glomerulosclerosis	0.000296	0.00149	CcSEcCtD
Sirolimus—FGF2—Developmental Biology—MYH10—focal segmental glomerulosclerosis	0.000295	0.00601	CbGpPWpGaD
Sirolimus—Malaise—Cyclosporine—focal segmental glomerulosclerosis	0.000292	0.00147	CcSEcCtD
Sirolimus—Leukopenia—Cyclosporine—focal segmental glomerulosclerosis	0.00029	0.00146	CcSEcCtD
Sirolimus—Cough—Cyclosporine—focal segmental glomerulosclerosis	0.000282	0.00142	CcSEcCtD
Sirolimus—MTOR—SREBP signalling—LPL—focal segmental glomerulosclerosis	0.00028	0.00572	CbGpPWpGaD
Sirolimus—Hypertension—Cyclosporine—focal segmental glomerulosclerosis	0.000279	0.00141	CcSEcCtD
Sirolimus—FGF2—Extracellular matrix organization—COL4A3—focal segmental glomerulosclerosis	0.000279	0.0057	CbGpPWpGaD
Sirolimus—MTOR—Signaling by PDGF—COL4A3—focal segmental glomerulosclerosis	0.000279	0.00569	CbGpPWpGaD
Sirolimus—FGF2—MicroRNAs in cardiomyocyte hypertrophy—AGT—focal segmental glomerulosclerosis	0.000276	0.00563	CbGpPWpGaD
Sirolimus—Chest pain—Cyclosporine—focal segmental glomerulosclerosis	0.000275	0.00139	CcSEcCtD
Sirolimus—Arthralgia—Cyclosporine—focal segmental glomerulosclerosis	0.000275	0.00139	CcSEcCtD
Sirolimus—Myalgia—Cyclosporine—focal segmental glomerulosclerosis	0.000275	0.00139	CcSEcCtD
Sirolimus—Anxiety—Cyclosporine—focal segmental glomerulosclerosis	0.000274	0.00138	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—focal segmental glomerulosclerosis	0.000274	0.00138	CcSEcCtD
Sirolimus—Discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.000272	0.00137	CcSEcCtD
Sirolimus—SLCO1B1—Bile acid and bile salt metabolism—ALB—focal segmental glomerulosclerosis	0.000266	0.00543	CbGpPWpGaD
Sirolimus—Confusional state—Cyclosporine—focal segmental glomerulosclerosis	0.000266	0.00134	CcSEcCtD
Sirolimus—Anaphylactic shock—Cyclosporine—focal segmental glomerulosclerosis	0.000264	0.00133	CcSEcCtD
Sirolimus—Oedema—Cyclosporine—focal segmental glomerulosclerosis	0.000264	0.00133	CcSEcCtD
Sirolimus—Infection—Cyclosporine—focal segmental glomerulosclerosis	0.000262	0.00132	CcSEcCtD
Sirolimus—FKBP1A—TGF-beta receptor signaling—TGFB1—focal segmental glomerulosclerosis	0.00026	0.00529	CbGpPWpGaD
Sirolimus—Nervous system disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000259	0.0013	CcSEcCtD
Sirolimus—Thrombocytopenia—Cyclosporine—focal segmental glomerulosclerosis	0.000259	0.0013	CcSEcCtD
Sirolimus—Skin disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000256	0.00129	CcSEcCtD
Sirolimus—Hyperhidrosis—Cyclosporine—focal segmental glomerulosclerosis	0.000255	0.00129	CcSEcCtD
Sirolimus—SLCO1B1—Transport of vitamins, nucleosides, and related molecules—ALB—focal segmental glomerulosclerosis	0.000255	0.0052	CbGpPWpGaD
Sirolimus—FKBP1A—Spinal Cord Injury—NOS2—focal segmental glomerulosclerosis	0.000254	0.00517	CbGpPWpGaD
Sirolimus—FKBP1A—TGF-beta Receptor Signaling—TGFB1—focal segmental glomerulosclerosis	0.000252	0.00514	CbGpPWpGaD
Sirolimus—Anorexia—Cyclosporine—focal segmental glomerulosclerosis	0.000252	0.00127	CcSEcCtD
Sirolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—EDN1—focal segmental glomerulosclerosis	0.000247	0.00504	CbGpPWpGaD
Sirolimus—MTOR—IL12-mediated signaling events—NOS2—focal segmental glomerulosclerosis	0.000245	0.005	CbGpPWpGaD
Sirolimus—Musculoskeletal discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.000241	0.00121	CcSEcCtD
Sirolimus—Insomnia—Cyclosporine—focal segmental glomerulosclerosis	0.000239	0.0012	CcSEcCtD
Sirolimus—Paraesthesia—Cyclosporine—focal segmental glomerulosclerosis	0.000237	0.00119	CcSEcCtD
Sirolimus—Dyspnoea—Cyclosporine—focal segmental glomerulosclerosis	0.000235	0.00119	CcSEcCtD
Sirolimus—Somnolence—Cyclosporine—focal segmental glomerulosclerosis	0.000235	0.00118	CcSEcCtD
Sirolimus—FGF2—Non-integrin membrane-ECM interactions—TGFB1—focal segmental glomerulosclerosis	0.000233	0.00476	CbGpPWpGaD
Sirolimus—Dyspepsia—Cyclosporine—focal segmental glomerulosclerosis	0.000232	0.00117	CcSEcCtD
Sirolimus—Decreased appetite—Cyclosporine—focal segmental glomerulosclerosis	0.00023	0.00116	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000228	0.00115	CcSEcCtD
Sirolimus—MTOR—Extracellular vesicle-mediated signaling in recipient cells—TGFB1—focal segmental glomerulosclerosis	0.000227	0.00462	CbGpPWpGaD
Sirolimus—Pain—Cyclosporine—focal segmental glomerulosclerosis	0.000226	0.00114	CcSEcCtD
Sirolimus—Constipation—Cyclosporine—focal segmental glomerulosclerosis	0.000226	0.00114	CcSEcCtD
Sirolimus—FGF2—Developmental Biology—COL4A4—focal segmental glomerulosclerosis	0.000218	0.00444	CbGpPWpGaD
Sirolimus—Feeling abnormal—Cyclosporine—focal segmental glomerulosclerosis	0.000218	0.0011	CcSEcCtD
Sirolimus—Gastrointestinal pain—Cyclosporine—focal segmental glomerulosclerosis	0.000216	0.00109	CcSEcCtD
Sirolimus—FGF2—Differentiation Pathway—TGFB1—focal segmental glomerulosclerosis	0.00021	0.00428	CbGpPWpGaD
Sirolimus—Abdominal pain—Cyclosporine—focal segmental glomerulosclerosis	0.000209	0.00105	CcSEcCtD
Sirolimus—Body temperature increased—Cyclosporine—focal segmental glomerulosclerosis	0.000209	0.00105	CcSEcCtD
Sirolimus—FGF2—B Cell Activation—CD79A—focal segmental glomerulosclerosis	0.000206	0.00419	CbGpPWpGaD
Sirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—PCNA—focal segmental glomerulosclerosis	0.000205	0.00419	CbGpPWpGaD
Sirolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—AGT—focal segmental glomerulosclerosis	0.000205	0.00418	CbGpPWpGaD
Sirolimus—FKBP1A—Loss of Function of SMAD2/3 in Cancer—TGFB1—focal segmental glomerulosclerosis	0.000205	0.00417	CbGpPWpGaD
Sirolimus—FGF2—Endochondral Ossification—MMP9—focal segmental glomerulosclerosis	0.000202	0.00412	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—PIAS1—focal segmental glomerulosclerosis	0.000202	0.00411	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—COL4A1—focal segmental glomerulosclerosis	0.0002	0.00408	CbGpPWpGaD
Sirolimus—Hypersensitivity—Cyclosporine—focal segmental glomerulosclerosis	0.000195	0.00098	CcSEcCtD
Sirolimus—FGF2—Cardiac Progenitor Differentiation—TGFB1—focal segmental glomerulosclerosis	0.000194	0.00395	CbGpPWpGaD
Sirolimus—MTOR—Oncostatin M Signaling Pathway—SERPINE1—focal segmental glomerulosclerosis	0.000193	0.00395	CbGpPWpGaD
Sirolimus—Asthenia—Cyclosporine—focal segmental glomerulosclerosis	0.000189	0.000954	CcSEcCtD
Sirolimus—SLC47A1—Transmembrane transport of small molecules—TRPC6—focal segmental glomerulosclerosis	0.000188	0.00384	CbGpPWpGaD
Sirolimus—FGF2—Cardiac Hypertrophic Response—TGFB1—focal segmental glomerulosclerosis	0.000188	0.00384	CbGpPWpGaD
Sirolimus—Pruritus—Cyclosporine—focal segmental glomerulosclerosis	0.000187	0.000941	CcSEcCtD
Sirolimus—MTOR—Senescence and Autophagy in Cancer—PCNA—focal segmental glomerulosclerosis	0.000186	0.0038	CbGpPWpGaD
Sirolimus—Diarrhoea—Cyclosporine—focal segmental glomerulosclerosis	0.000181	0.00091	CcSEcCtD
Sirolimus—Dizziness—Cyclosporine—focal segmental glomerulosclerosis	0.000175	0.00088	CcSEcCtD
Sirolimus—FGF2—Developmental Biology—COL4A3—focal segmental glomerulosclerosis	0.000169	0.00345	CbGpPWpGaD
Sirolimus—Vomiting—Cyclosporine—focal segmental glomerulosclerosis	0.000168	0.000846	CcSEcCtD
Sirolimus—FGF2—Endochondral Ossification—TGFB1—focal segmental glomerulosclerosis	0.000167	0.0034	CbGpPWpGaD
Sirolimus—Rash—Cyclosporine—focal segmental glomerulosclerosis	0.000166	0.000839	CcSEcCtD
Sirolimus—Dermatitis—Cyclosporine—focal segmental glomerulosclerosis	0.000166	0.000838	CcSEcCtD
Sirolimus—Headache—Cyclosporine—focal segmental glomerulosclerosis	0.000165	0.000833	CcSEcCtD
Sirolimus—FGF2—Signaling by PDGF—SPP1—focal segmental glomerulosclerosis	0.000165	0.00336	CbGpPWpGaD
Sirolimus—FKBP1A—Spinal Cord Injury—MMP9—focal segmental glomerulosclerosis	0.000164	0.00334	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—MYH9—focal segmental glomerulosclerosis	0.000161	0.00329	CbGpPWpGaD
Sirolimus—FGF2—Regulation of Actin Cytoskeleton—FN1—focal segmental glomerulosclerosis	0.000161	0.00329	CbGpPWpGaD
Sirolimus—MTOR—Senescence and Autophagy in Cancer—FN1—focal segmental glomerulosclerosis	0.000158	0.00323	CbGpPWpGaD
Sirolimus—Nausea—Cyclosporine—focal segmental glomerulosclerosis	0.000157	0.00079	CcSEcCtD
Sirolimus—FGF2—Integrated Pancreatic Cancer Pathway—PCNA—focal segmental glomerulosclerosis	0.000156	0.00317	CbGpPWpGaD
Sirolimus—SLC47A1—SLC-mediated transmembrane transport—ALB—focal segmental glomerulosclerosis	0.000153	0.00312	CbGpPWpGaD
Sirolimus—MTOR—B Cell Activation—CD79A—focal segmental glomerulosclerosis	0.000153	0.00311	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—MYH9—focal segmental glomerulosclerosis	0.000149	0.00305	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PIAS1—focal segmental glomerulosclerosis	0.000149	0.00304	CbGpPWpGaD
Sirolimus—MTOR—BDNF signaling pathway—SPP1—focal segmental glomerulosclerosis	0.000147	0.00301	CbGpPWpGaD
Sirolimus—EIF4E—Metabolism of proteins—ACE—focal segmental glomerulosclerosis	0.000147	0.00299	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—MYH9—focal segmental glomerulosclerosis	0.000143	0.00291	CbGpPWpGaD
Sirolimus—MTOR—Cardiac Hypertrophic Response—TGFB1—focal segmental glomerulosclerosis	0.00014	0.00285	CbGpPWpGaD
Sirolimus—FKBP1A—Spinal Cord Injury—TGFB1—focal segmental glomerulosclerosis	0.000135	0.00275	CbGpPWpGaD
Sirolimus—FGF2—MicroRNAs in cardiomyocyte hypertrophy—TGFB1—focal segmental glomerulosclerosis	0.000134	0.00273	CbGpPWpGaD
Sirolimus—MTOR—Senescence and Autophagy in Cancer—SERPINE1—focal segmental glomerulosclerosis	0.000132	0.00269	CbGpPWpGaD
Sirolimus—ABCB1—Allograft Rejection—AGTR1—focal segmental glomerulosclerosis	0.000132	0.00269	CbGpPWpGaD
Sirolimus—MTOR—EGF/EGFR Signaling Pathway—PCNA—focal segmental glomerulosclerosis	0.000132	0.00269	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	0.00013	0.00266	CbGpPWpGaD
Sirolimus—ABCB1—HIF-1-alpha transcription factor network—EDN1—focal segmental glomerulosclerosis	0.000129	0.00263	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—TRPC6—focal segmental glomerulosclerosis	0.000124	0.00254	CbGpPWpGaD
Sirolimus—FGF2—Extracellular matrix organization—SPP1—focal segmental glomerulosclerosis	0.000122	0.00249	CbGpPWpGaD
Sirolimus—MTOR—Signaling by PDGF—SPP1—focal segmental glomerulosclerosis	0.000122	0.00249	CbGpPWpGaD
Sirolimus—MTOR—CXCR4-mediated signaling events—MMP9—focal segmental glomerulosclerosis	0.000121	0.00246	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	0.00012	0.00244	CbGpPWpGaD
Sirolimus—MTOR—Regulation of Telomerase—TGFB1—focal segmental glomerulosclerosis	0.000118	0.0024	CbGpPWpGaD
Sirolimus—FGF2—Immune System—PIAS1—focal segmental glomerulosclerosis	0.000112	0.00229	CbGpPWpGaD
Sirolimus—ABCB1—Allograft Rejection—CD40LG—focal segmental glomerulosclerosis	0.00011	0.00225	CbGpPWpGaD
Sirolimus—FGF2—Signaling by SCF-KIT—MMP9—focal segmental glomerulosclerosis	0.000107	0.00219	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—MYH9—focal segmental glomerulosclerosis	0.000106	0.00216	CbGpPWpGaD
Sirolimus—EIF4E—Gene Expression—CTGF—focal segmental glomerulosclerosis	0.000104	0.00212	CbGpPWpGaD
Sirolimus—FGF2—Extracellular matrix organization—FN1—focal segmental glomerulosclerosis	0.000102	0.00208	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	0.000101	0.00206	CbGpPWpGaD
Sirolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—TGFB1—focal segmental glomerulosclerosis	9.95e-05	0.00203	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—focal segmental glomerulosclerosis	9.83e-05	0.002	CbGpPWpGaD
Sirolimus—ABCB1—HIF-1-alpha transcription factor network—NOS2—focal segmental glomerulosclerosis	9.77e-05	0.00199	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	9.56e-05	0.00195	CbGpPWpGaD
Sirolimus—EIF4E—Metabolism of proteins—AGT—focal segmental glomerulosclerosis	9.29e-05	0.0019	CbGpPWpGaD
Sirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TGFB1—focal segmental glomerulosclerosis	9.17e-05	0.00187	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—CD79A—focal segmental glomerulosclerosis	9.05e-05	0.00185	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	8.79e-05	0.00179	CbGpPWpGaD
Sirolimus—FGF2—Extracellular matrix organization—MMP2—focal segmental glomerulosclerosis	8.66e-05	0.00177	CbGpPWpGaD
Sirolimus—FGF2—Extracellular matrix organization—SERPINE1—focal segmental glomerulosclerosis	8.5e-05	0.00173	CbGpPWpGaD
Sirolimus—MTOR—Senescence and Autophagy in Cancer—TGFB1—focal segmental glomerulosclerosis	8.32e-05	0.0017	CbGpPWpGaD
Sirolimus—MTOR—Immune System—PIAS1—focal segmental glomerulosclerosis	8.32e-05	0.0017	CbGpPWpGaD
Sirolimus—FGF2—Immune System—MYH9—focal segmental glomerulosclerosis	8.3e-05	0.00169	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—CD79A—focal segmental glomerulosclerosis	8.29e-05	0.00169	CbGpPWpGaD
Sirolimus—ABCB1—HIF-1-alpha transcription factor network—SERPINE1—focal segmental glomerulosclerosis	8.23e-05	0.00168	CbGpPWpGaD
Sirolimus—MTOR—Signaling by SCF-KIT—MMP9—focal segmental glomerulosclerosis	7.98e-05	0.00163	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—LPL—focal segmental glomerulosclerosis	7.82e-05	0.0016	CbGpPWpGaD
Sirolimus—SLC47A1—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	7.78e-05	0.00159	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	7.44e-05	0.00152	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	7.42e-05	0.00151	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	7.4e-05	0.00151	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—CD40LG—focal segmental glomerulosclerosis	7.38e-05	0.0015	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	7.31e-05	0.00149	CbGpPWpGaD
Sirolimus—EIF4E—Metabolism of proteins—MMP2—focal segmental glomerulosclerosis	7.28e-05	0.00148	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	7.25e-05	0.00148	CbGpPWpGaD
Sirolimus—FGF2—Integrated Pancreatic Cancer Pathway—TGFB1—focal segmental glomerulosclerosis	6.95e-05	0.00142	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—CD40LG—focal segmental glomerulosclerosis	6.76e-05	0.00138	CbGpPWpGaD
Sirolimus—SLCO1B1—Transmembrane transport of small molecules—TRPC6—focal segmental glomerulosclerosis	6.74e-05	0.00138	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	6.66e-05	0.00136	CbGpPWpGaD
Sirolimus—FGF2—Extracellular matrix organization—MMP9—focal segmental glomerulosclerosis	6.51e-05	0.00133	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	6.43e-05	0.00131	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	6.22e-05	0.00127	CbGpPWpGaD
Sirolimus—MTOR—Immune System—MYH9—focal segmental glomerulosclerosis	6.16e-05	0.00126	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—CD79A—focal segmental glomerulosclerosis	6.15e-05	0.00126	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	5.69e-05	0.00116	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	5.63e-05	0.00115	CbGpPWpGaD
Sirolimus—SLCO1B1—SLC-mediated transmembrane transport—ALB—focal segmental glomerulosclerosis	5.48e-05	0.00112	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	5.46e-05	0.00111	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	5.43e-05	0.00111	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	5.38e-05	0.0011	CbGpPWpGaD
Sirolimus—FGF2—Extracellular matrix organization—TGFB1—focal segmental glomerulosclerosis	5.36e-05	0.00109	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—MMP2—focal segmental glomerulosclerosis	5.24e-05	0.00107	CbGpPWpGaD
Sirolimus—FGF2—Immune System—CD79A—focal segmental glomerulosclerosis	5.03e-05	0.00103	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—CD40LG—focal segmental glomerulosclerosis	5.02e-05	0.00102	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—focal segmental glomerulosclerosis	4.97e-05	0.00101	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	4.94e-05	0.00101	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—LPL—focal segmental glomerulosclerosis	4.9e-05	0.001	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	4.82e-05	0.000984	CbGpPWpGaD
Sirolimus—EIF4E—Gene Expression—SERPINE1—focal segmental glomerulosclerosis	4.74e-05	0.000966	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—LPL—focal segmental glomerulosclerosis	4.68e-05	0.000955	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	4.56e-05	0.000931	CbGpPWpGaD
Sirolimus—ABCB1—Allograft Rejection—TGFB1—focal segmental glomerulosclerosis	4.5e-05	0.000917	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	4.46e-05	0.000909	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	4.43e-05	0.000904	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	4.18e-05	0.000852	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	4.17e-05	0.000851	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	4.14e-05	0.000844	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	4.11e-05	0.000839	CbGpPWpGaD
Sirolimus—FGF2—Immune System—CD40LG—focal segmental glomerulosclerosis	4.1e-05	0.000836	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—AGT—focal segmental glomerulosclerosis	4e-05	0.000817	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—MMP9—focal segmental glomerulosclerosis	3.94e-05	0.000804	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—NOS2—focal segmental glomerulosclerosis	3.83e-05	0.000781	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	3.82e-05	0.000778	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CD79A—focal segmental glomerulosclerosis	3.73e-05	0.000761	CbGpPWpGaD
Sirolimus—FGF2—Disease—LPL—focal segmental glomerulosclerosis	3.72e-05	0.000758	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—FN1—focal segmental glomerulosclerosis	3.7e-05	0.000755	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	3.54e-05	0.000722	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	3.46e-05	0.000705	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—LPL—focal segmental glomerulosclerosis	3.43e-05	0.0007	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—TRPC6—focal segmental glomerulosclerosis	3.38e-05	0.000688	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—LIPC—focal segmental glomerulosclerosis	3.25e-05	0.000664	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	3.25e-05	0.000663	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—TGFB1—focal segmental glomerulosclerosis	3.25e-05	0.000663	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—SERPINE1—focal segmental glomerulosclerosis	3.23e-05	0.000658	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	3.16e-05	0.000645	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	3.08e-05	0.000628	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	3.07e-05	0.000626	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	3.05e-05	0.000623	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CD40LG—focal segmental glomerulosclerosis	3.04e-05	0.000621	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—LIPC—focal segmental glomerulosclerosis	2.99e-05	0.000609	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—AGT—focal segmental glomerulosclerosis	2.94e-05	0.000599	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	2.93e-05	0.000597	CbGpPWpGaD
Sirolimus—FGF2—Disease—NOS2—focal segmental glomerulosclerosis	2.9e-05	0.000592	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—CTGF—focal segmental glomerulosclerosis	2.87e-05	0.000584	CbGpPWpGaD
Sirolimus—SLCO1B1—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	2.78e-05	0.000568	CbGpPWpGaD
Sirolimus—MTOR—Disease—LPL—focal segmental glomerulosclerosis	2.76e-05	0.000562	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—FN1—focal segmental glomerulosclerosis	2.71e-05	0.000554	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	2.68e-05	0.000547	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—GNAQ—focal segmental glomerulosclerosis	2.64e-05	0.000538	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—CTGF—focal segmental glomerulosclerosis	2.63e-05	0.000536	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—LPL—focal segmental glomerulosclerosis	2.6e-05	0.000531	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	2.57e-05	0.000523	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	2.46e-05	0.000503	CbGpPWpGaD
Sirolimus—FGF2—Disease—SERPINE1—focal segmental glomerulosclerosis	2.44e-05	0.000498	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—GNAQ—focal segmental glomerulosclerosis	2.42e-05	0.000494	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	2.36e-05	0.000481	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	2.35e-05	0.000479	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	2.26e-05	0.000461	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—AGT—focal segmental glomerulosclerosis	2.23e-05	0.000454	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—focal segmental glomerulosclerosis	2.22e-05	0.000453	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—LIPC—focal segmental glomerulosclerosis	2.16e-05	0.00044	CbGpPWpGaD
Sirolimus—MTOR—Disease—NOS2—focal segmental glomerulosclerosis	2.15e-05	0.000439	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—FN1—focal segmental glomerulosclerosis	2.06e-05	0.000419	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—TGFB1—focal segmental glomerulosclerosis	2.04e-05	0.000415	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	1.99e-05	0.000406	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—LPL—focal segmental glomerulosclerosis	1.99e-05	0.000405	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	1.94e-05	0.000396	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—LPL—focal segmental glomerulosclerosis	1.93e-05	0.000394	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CTGF—focal segmental glomerulosclerosis	1.9e-05	0.000388	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	1.83e-05	0.000373	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—LPL—focal segmental glomerulosclerosis	1.82e-05	0.000372	CbGpPWpGaD
Sirolimus—MTOR—Disease—SERPINE1—focal segmental glomerulosclerosis	1.81e-05	0.00037	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—GNAQ—focal segmental glomerulosclerosis	1.75e-05	0.000357	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.73e-05	0.000353	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.71e-05	0.000349	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—AGT—focal segmental glomerulosclerosis	1.7e-05	0.000346	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—AGT—focal segmental glomerulosclerosis	1.65e-05	0.000337	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—LIPC—focal segmental glomerulosclerosis	1.63e-05	0.000332	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—AGT—focal segmental glomerulosclerosis	1.56e-05	0.000318	CbGpPWpGaD
Sirolimus—FGF2—Disease—TGFB1—focal segmental glomerulosclerosis	1.54e-05	0.000315	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1.53e-05	0.000311	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CTGF—focal segmental glomerulosclerosis	1.43e-05	0.000293	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	1.43e-05	0.000291	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	1.39e-05	0.000284	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GNAQ—focal segmental glomerulosclerosis	1.32e-05	0.00027	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—LPL—focal segmental glomerulosclerosis	1.32e-05	0.000269	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.31e-05	0.000267	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—ALB—focal segmental glomerulosclerosis	1.3e-05	0.000266	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.27e-05	0.000259	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—ALB—focal segmental glomerulosclerosis	1.2e-05	0.000244	CbGpPWpGaD
Sirolimus—MTOR—Disease—TGFB1—focal segmental glomerulosclerosis	1.15e-05	0.000234	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—AGT—focal segmental glomerulosclerosis	1.13e-05	0.00023	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	1.08e-05	0.00022	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—LIPC—focal segmental glomerulosclerosis	1e-05	0.000205	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—LPL—focal segmental glomerulosclerosis	9.94e-06	0.000203	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	9.73e-06	0.000198	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CTGF—focal segmental glomerulosclerosis	8.84e-06	0.00018	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—ALB—focal segmental glomerulosclerosis	8.65e-06	0.000176	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—AGT—focal segmental glomerulosclerosis	8.51e-06	0.000173	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GNAQ—focal segmental glomerulosclerosis	8.14e-06	0.000166	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	8.02e-06	0.000164	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—ALB—focal segmental glomerulosclerosis	6.53e-06	0.000133	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—LPL—focal segmental glomerulosclerosis	6.13e-06	0.000125	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—AGT—focal segmental glomerulosclerosis	5.24e-06	0.000107	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ALB—focal segmental glomerulosclerosis	4.02e-06	8.2e-05	CbGpPWpGaD
